Raymond Joseph Tesi net worth and biography

Raymond Tesi Biography and Net Worth

CEO of INmune Bio

Dr. Tesi has been our President, Chief Executive Officer and acting Chief Medical Officer since the formation of the Company in September 2015. From November 2011 to May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development-stage biotech company formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech company in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was CEO and President of Coronado Biosciences, a company he founded. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982 and Fellow of the American College of Surgery since 1991.

What is Raymond Joseph Tesi's net worth?: The estimated net worth of Raymond Joseph Tesi is at least $8.39 million as of September 12th, 2024. Dr. Tesi owns 1,554,106 shares of INmune Bio stock worth more than $8,392,172 as of December 3rd. This net worth estimate does not reflect any other assets that Dr. Tesi may own. Additionally, Dr. Tesi receives an annual salary of $500,500.00 as CEO at INmune Bio. Learn More about Raymond Joseph Tesi's net worth.
How old is Raymond Joseph Tesi?: Dr. Tesi is currently 68 years old. There are 2 older executives and no younger executives at INmune Bio. Learn More on Raymond Joseph Tesi's age.
What is Raymond Joseph Tesi's salary?: As the CEO of INmune Bio, Inc., Dr. Tesi earns $500,500.00 per year. Learn More on Raymond Joseph Tesi's salary.
How do I contact Raymond Joseph Tesi?: The corporate mailing address for Dr. Tesi and other INmune Bio executives is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. INmune Bio can also be reached via phone at (858) 964-3720 and via email at [email protected]. Learn More on Raymond Joseph Tesi's contact information.
Has Raymond Joseph Tesi been buying or selling shares of INmune Bio?: Raymond Joseph Tesi has not been actively trading shares of INmune Bio during the last ninety days. Most recently, on Thursday, September 12th, Raymond Joseph Tesi bought 15,380 shares of INmune Bio stock. The stock was acquired at an average cost of $6.38 per share, with a total value of $98,124.40. Following the completion of the transaction, the chief executive officer now directly owns 1,554,106 shares of the company's stock, valued at $9,915,196.28. Learn More on Raymond Joseph Tesi's trading history.
Who are INmune Bio's active insiders?: INmune Bio's insider roster includes Mark Lowdell (Insider), David Moss (CFO), Timothy Schroeder (Director), and Raymond Tesi (CEO). Learn More on INmune Bio's active insiders.
Are insiders buying or selling shares of INmune Bio?: During the last twelve months, INmune Bio insiders bought shares 4 times. They purchased a total of 38,070 shares worth more than $236,436.60. The most recent insider tranaction occured on September, 30th when CFO David J Moss bought 10,000 shares worth more than $52,900.00. Insiders at INmune Bio own 35.2% of the company. Learn More about insider trades at INmune Bio.
Information on this page was last updated on 9/30/2024.

Raymond Joseph Tesi Insider Trading History at INmune Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/12/2024	Buy	15,380	$6.38	$98,124.40	1,554,106
5/26/2022	Buy	6,300	$6.41	$40,383.00	1,520,698
11/3/2021	Sell	3,626	$20.00	$72,520.00
10/27/2021	Sell	6,517	$20.00	$130,340.00
10/22/2021	Sell	23,616	$20.00	$472,320.00
7/7/2021	Sell	5,649	$20.02	$113,092.98	1,535,284
8/20/2019	Buy	2,000	$5.99	$11,980.00
8/9/2019	Buy	2,000	$7.03	$14,060.00
6/3/2019	Buy	10,000	$6.00	$60,000.00
5/2/2019	Buy	11,100	$9.90	$109,890.00

Raymond Joseph Tesi Buying and Selling Activity at INmune Bio

INmune Bio Company Overview

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Today's Range

Now: $5.40

$5.40

$5.76

50 Day Range

MA: $5.35

$4.56

$6.43

2 Week Range

Now: $5.40

$4.45

$14.74

Volume

165,998 shs

Average Volume

165,323 shs

Market Capitalization

$119.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

Raymond Tesi Biography and Net Worth

What is Raymond Joseph Tesi's net worth?

How old is Raymond Joseph Tesi?

What is Raymond Joseph Tesi's salary?

How do I contact Raymond Joseph Tesi?

Has Raymond Joseph Tesi been buying or selling shares of INmune Bio?

Who are INmune Bio's active insiders?

Are insiders buying or selling shares of INmune Bio?